Giordano Raffaele, Arcieri Luigi, Cantinotti Massimiliano, Pak Vitali, Poli Vincenzo, Maizza Anna, Melo Manuel, Assanta Nadia, Moschetti Riccardo, Murzi Bruno
Department of Pediatric Cardiology and Cardiac Surgery, Tuscany Foundation "G. Monasterio," Massa, MS, Italy.
Thorac Cardiovasc Surg. 2016 Jan;64(1):53-8. doi: 10.1055/s-0035-1566235. Epub 2015 Nov 24.
The cardioplegia is one of the most significant tools used to increase myocardial protection. The aim of our study is to compare the use of Custodiol solution versus intermitted blood cardioplegia in a retrospective analysis of data for patients who underwent arterial switch operation in our institution.
From January 2008 to March 2011, myocardial protection was performed in 44 neonates (blood group) with intermittent blood cardioplegia. From March 2011 to November 2014, myocardial protection was performed in 50 neonates (Custodiol group) with one-shot anterograde Custodiol cardioplegia.
Cardiopulmonary bypass and aortic cross-clamp were more favorable in Custodiol group (p-value 0.005 and ≤ 0.00001). The rate of delayed sternal closure was 63.6% in the blood group and 52% in the Custodiol group (p = 0.25). In the postoperative outcomes we did not find differences between the two groups. The 30-day mortality was one patient in the blood group (p = 0.46). We observed a transient ischemic electrocardiogram in 10 patients of the blood group and in 14 of the Custodiol group (p = 0.72), all cases with full resolution during hospitalization without coronary reoperation. A trend of higher peak of troponin-I and brain natriuretic peptide in Custodiol group has been reported.
No prefect cardioplegia exists, the Custodiol solution does not cause extra/additional myocardial damage in arterial switch operation. In our experience this strategy seems warranted to simplify the procedure and to be more comfortable for the surgeon.
心脏停搏液是增强心肌保护的最重要工具之一。我们研究的目的是在对我院接受动脉调转术患者的数据进行回顾性分析中,比较使用科停液(Custodiol溶液)与间歇性冷血心脏停搏液的效果。
2008年1月至2011年3月,对44例新生儿(血型)采用间歇性冷血心脏停搏液进行心肌保护。2011年3月至2014年11月,对50例新生儿(科停液组)采用单次顺行性科停液心脏停搏进行心肌保护。
科停液组的体外循环和主动脉阻断情况更有利(p值分别为0.005和≤0.00001)。血型组延迟关胸率为63.6%,科停液组为52%(p = 0.25)。在术后结果方面,两组之间未发现差异。血型组30天死亡率为1例患者(p = 0.46)。我们观察到血型组10例患者和科停液组14例患者出现短暂性缺血性心电图(p = 0.72),所有病例在住院期间均完全恢复,无需再次进行冠状动脉手术。据报道,科停液组肌钙蛋白-I和脑钠肽的峰值有升高趋势。
不存在完美的心脏停搏液,在动脉调转术中,科停液不会造成额外的心肌损伤。根据我们的经验,这种策略似乎有助于简化手术过程,让外科医生操作起来更轻松。